Genetics 101 for Cardiologists: Rare Genetic Variants and Monogenic Cardiovascular Disease

Canadian Journal of Cardiology

Volumn 29, Issue 1, 2013, Pages 18-22

  Farhan, Sali M K ^a   Hegele, Robert A ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN LIKE PROTEIN 3; APOLIPOPROTEIN B; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DNA SEQUENCE; EXOME; EXON; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; GENETIC VARIABILITY; HERITABILITY; HETEROZYGOSITY; HUMAN; INTRON; LONG QT SYNDROME; PHENOTYPE; RARE DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DNA; GENOTYPE; HUMANS; MUTATION; PHENOTYPE;

EID: 84871449471     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.10.010     Document Type: Article

References (21)

1. Lanktree M.B., Hegele R.A. Gene-gene and gene-environment interactions: new insights into the prevention, detection and management of coronary artery disease. Genome Med 2009, 1:28.
2. O'Donnell C.J., Nabel E.G. Genomics of cardiovascular disease. N Engl J Med 2011, 365:2098-2109.
3. Nabel E.G. Cardiovascular disease. N Engl J Med 2003, 349:60-72.
4. Antonarakis S.E., Beckmann J.S. Mendelian disorders deserve more attention. Nat Rev Genet 2006, 4:277-282.
5. Rahalkar A.R., Hegele R.A. Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum. Mol Genet Metab 2008, 93:282-294.
6. Nehring W.M., Faux S.A. Clinical genetics: an overview. J Cardiovasc Nurs 1999, 4:19-33.
7. Hegele R.A. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009, 10:109-121.
8. Pollex R.L., Hegele R.A. Copy number variation in the human genome and its implications for cardiovascular disease. Circulation 2007, 115:3130-3138.
9. Bick D., Dimmock D. Whole exome and whole genome sequencing. Curr Opin Pediatr 2011, 23:594-600.
10. Majewski J., Schwartzentruber J., Lalonde E., et al. What can exome sequencing do for you?. J Med Genet 2011, 48:580-589.
11. Glissen C., Hoischen A., Brunner H.G., et al. Unlocking Mendelian disease using exome sequencing. Genome Biol 2011, 12:228-239.
12. Lahiry P., Wang J., Robinson J.F., et al. A multiplex human syndrome implicates a key role for intestinal cell kinase in development of central nervous, skeletal, and endocrine systems. Am J Hum Genet 2009, 84:134-147.
13. Hegele R.A., Reue K. Hoofbeats, zebras, and insights into insulin resistance. J Clin Invest 2009, 119:249-251.
14. Yuan G., Wang J., Hegele R.A. Heterozygous familial hypercholesterolemia: an under-recognized cause of early cardiovascular disease. CMAJ 2006, 174:1124-1129.
15. Goldstein J.L., Brown M.S. The LDL receptor. Arterioscler Thromb Vasc Biol 2009, 29:431-438.
16. Mihaylova B., Emberson J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. Cholesterol Treatment Trialists' (CTT) Collaborators.
17. Cohen J.C., Boerwinkle E., Mosley T.H., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
18. Stein E.A., Mellis S., Yancopoulos G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366:1108-1118.
19. Torkamani A., Scott-Van Zeeland A.A., Topol E.J., et al. Annotating individual human genomes. Genomics 2011, 98:233-241.
20. Musunuru K., Kathiresan S. Genetics of coronary artery disease. Annu Rev Genomics Hum Genet 2010, 11:91-108.
21. Scriver C.R. Science, medicine and phenylketonuria. Acta Paediatr Suppl 1994, 407:11-18.